View in EDS

Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine

Saved in:
Bibliographic Details
Title: Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Authors: Solfrid Thunold, Eivor Hernes, Saima Farooqi, Åsa Kristina Öjlert, Roslyn J. Francis, Anna K. Nowak, Weronika Maria Szejniuk, Søren Steen Nielsen, Susana Cedres, Marc Simo Perdigo, Jens Benn Sørensen, Carin Meltzer, Lars Tore Gyland Mikalsen, Åslaug Helland, Eirik Malinen, Vilde Drageset Haakensen
Contributors: Institut Català de la Salut, [Thunold S, Farooqi S, Öjlert ÅK] Dept of Oncology, Oslo University Hospital, Oslo, Norway. Dept of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. [Hernes E] Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway. [Francis RJ] Dept of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia. Medical School of The University of Western Australia, Perth, Australia. [Nowak AK] Medical School of The University of Western Australia, Perth, Australia. National Centre for Asbestos-Related Diseases, University of Western Australia, Perth, Australia. Medical Oncology, Sir Charles Gairdner Hospital, Perth, Australia. [Cedres S] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Simo Perdigo M] Servei de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus
Source: Eur J Nucl Med Mol Imaging
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Thunold, S, Hernes, E, Farooqi, S, Öjlert, Å K, Francis, R J, Nowak, A K, Szejniuk, W M, Nielsen, S S, Cedres, S, Perdigo, M S, Sørensen, J B, Meltzer, C, Mikalsen, L T G, Helland, Å, Malinen, E & Haakensen, V D 2025, 'Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/-UV1 telomerase vaccine', European Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 2, pp. 693–707. https://doi.org/10.1007/s00259-024-06853-0
European Journal of Nuclear Medicine and Molecular Imaging
Thunold, S, Hernes, E, Farooqi, S, Öjlert, Å K, Francis, R J, Nowak, A K, Szejniuk, W M, Nielsen, S S, Cedres, S, Perdigo, M S, Sørensen, J B, Meltzer, C, Mikalsen, L T G, Helland, Å, Malinen, E & Haakensen, V D 2025, ' Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/-UV1 telomerase vaccine ', European Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 2, pp. 693-707 . https://doi.org/10.1007/s00259-024-06853-0
Publisher Information: Springer Science and Business Media LLC, 2024.
Publication Year: 2024
Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::diagnóstico por imagen::interpretación de imágenes asistida por ordenador::tomografía computarizada radioisotópica::tomografía por emisión de positrones::tomografía por emisión de positrones-tomografía computarizada, MTV, DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma::Mesothelioma, Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Imaging::Image Interpretation, Computer-Assisted::Tomography, Emission-Computed::Positron-Emission Tomography::Positron Emission Tomography Computed Tomography, 03 medical and health sciences, 0302 clinical medicine, Telomerase vaccine, Pleural mesothelioma, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Combined Modality Therapy, Other subheadings::Other subheadings::Other subheadings::/drug therapy, ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pleurales, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, Pleura - Càncer - Immunoteràpia, SUV, 3. Good health, [18F]FDG PET, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento, Avaluació de resultats (Assistència sanitària), Tomografia per emissió de positrons, Original Article, Immunotherapy, Mesotelioma - Immunoteràpia, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma::mesotelioma, DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Pleural Neoplasms, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento combinado
Description: Purpose The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy. Methods Patients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included. [18F]FDG PET/CT was obtained at baseline (n = 100) and at week-5 (n = 76). Metabolic tumour volume (MTV) and peak standardised uptake value (SUVpeak) were evaluated in relation to survival outcomes. Wilcoxon rank-sum test was used to assess differences in MTV, total lesion glycolysis (TLG), maximum standardised uptake value (SUVmax) and SUVpeak between patients exhibiting an objective response, defined as either partial response or complete response according to the modified Response Criteria in Solid Tumours (mRECIST) and immune RECIST (iRECIST), and non-responders, defined as either stable disease or progressive disease as their best overall response. Results Univariate Cox regression revealed significant associations of MTV with OS (HR 1.36, CI: 1.14, 1.62, p < 0.001) and PFS (HR 1.18, CI: 1.03, 1.34, p = 0.02), while multivariate analysis showed a significant association with OS only (HR 1.35, CI: 1.09, 1.68, p = 0.007). While SUVpeak was not significantly associated with OS or PFS in univariate analyses, it was significantly associated with OS in multivariate analysis (HR 0.43, CI: 0.23, 0.80, p = 0.008). Objective responders had significant reductions in TLG, SUVmax and SUVpeak at week-5. Conclusion MTV provides prognostic value in PM treated with immunotherapy. High SUVpeak was not associated with inferior outcomes, which could be attributed to the distinct mechanisms of immunotherapy. Early reductions in PET metrics correlated with treatment response. Study registration The NIPU trial (NCT04300244) is registered at clinicaltrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT04300244?cond=Pleural+Mesothelioma&cntry=NO&draw=2&rank=4
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 1619-7089
1619-7070
DOI: 10.1007/s00259-024-06853-0
Access URL: https://pubmed.ncbi.nlm.nih.gov/39133306
https://hdl.handle.net/11351/12682
https://vbn.aau.dk/ws/files/767420804/Thunold_et_al._2025_._Outcome_prediction_based_on_18F_FDG_PET-CT_in_patients_with_pleural_mesothelioma_treated_with_ipilimumab_and_nivolumab_-_UV1_telomerase_vaccine.pdf
http://www.scopus.com/inward/record.url?scp=85201264245&partnerID=8YFLogxK
https://vbn.aau.dk/da/publications/64f8a3f5-fbf2-43a0-977e-4901dd192f43
https://doi.org/10.1007/s00259-024-06853-0
https://hdl.handle.net/11250/3178536
https://curis.ku.dk/ws/files/424525829/s00259_024_06853_0_1_.pdf
Rights: CC BY
URL: http://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (http://creativecommons.org/licenses/by/4.0/) .
Accession Number: edsair.doi.dedup.....5cc8eb907d74901d91cc57c6b5f2643e
Database: OpenAIRE
Description
Abstract:Purpose The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy. Methods Patients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included. [18F]FDG PET/CT was obtained at baseline (n = 100) and at week-5 (n = 76). Metabolic tumour volume (MTV) and peak standardised uptake value (SUVpeak) were evaluated in relation to survival outcomes. Wilcoxon rank-sum test was used to assess differences in MTV, total lesion glycolysis (TLG), maximum standardised uptake value (SUVmax) and SUVpeak between patients exhibiting an objective response, defined as either partial response or complete response according to the modified Response Criteria in Solid Tumours (mRECIST) and immune RECIST (iRECIST), and non-responders, defined as either stable disease or progressive disease as their best overall response. Results Univariate Cox regression revealed significant associations of MTV with OS (HR 1.36, CI: 1.14, 1.62, p < 0.001) and PFS (HR 1.18, CI: 1.03, 1.34, p = 0.02), while multivariate analysis showed a significant association with OS only (HR 1.35, CI: 1.09, 1.68, p = 0.007). While SUVpeak was not significantly associated with OS or PFS in univariate analyses, it was significantly associated with OS in multivariate analysis (HR 0.43, CI: 0.23, 0.80, p = 0.008). Objective responders had significant reductions in TLG, SUVmax and SUVpeak at week-5. Conclusion MTV provides prognostic value in PM treated with immunotherapy. High SUVpeak was not associated with inferior outcomes, which could be attributed to the distinct mechanisms of immunotherapy. Early reductions in PET metrics correlated with treatment response. Study registration The NIPU trial (NCT04300244) is registered at clinicaltrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT04300244?cond=Pleural+Mesothelioma&cntry=NO&draw=2&rank=4
ISSN:16197089
16197070
DOI:10.1007/s00259-024-06853-0